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Does soy increase blood counts in myelodysplastic syndromes?
Será que a soja aumenta as contagens sanguíneas em síndrome mielodisplásica?
T. A. O. F. Viana1; E. Claricia1; R. F. Pinheiro1; M. C. C. Panizzi2; A. F. Sandes1; V. M. Carvalho3; 
R. C. C. Sesso4; M. Yamamoto1; A. n. Atallah4; M. L. L. F. Chauffaille1
Myelodysplastic syndromes (MDS) are a group of clonal stem cell diseases characterized by 
ineffective hematopoiesis, bone marrow hyperproliferation, cytopenias in peripheral blood and risk 
of transformation into acute leukemia. We decided to investigate the effects of a soy concentrate 
on MDS patients based on the follow-up results of a 61 year-old Japanese female patient who was 
diagnosed with MDS and refractory cytopenia with multilineage dysplasia in 2003 (hemoglobin = 
11g/dL; white blood cells count = 2,500/uL and platelets = 25,000/uL; marrow with mild dysplasia 
and normal karyotype; paroxysmal nocturnal hemoglobinuria was excluded). She started using soy 
as a dietary supplementation in May 2004 and presented a gradual increment in blood counts, 
achieving normalization approximately eight months afterwards. Among the soy components, the 
main compounds with anti-carcinogenic activity are the isoflavones (genistein and daidzein). Based 
on these lines of evidence, we proposed to administer daily a standard soy concentrate to 14 MDS 
out-patients for a minimum period of three months and maximum of 12 months, in an attempt to 
evaluate prospectively the possible increase in hemoglobin, neutrophils and platelet counts. A historical 
control group was used to compare results. The use of a soy concentrate in a standardized manner 
was associated with an increase in neutrophil and/or platelet counts in some cases, but spontaneous 
increments were also observed in historical controls. This preliminary study does not allow establishing 
a relation between soy supplementation and blood cell count increase.
abstractkey words
Soy
White blood counts
Myelodysplastic syndrome
Isoflavones
Hemoglobin
Platelet
resumo 
As síndromes mielodisplásicas (SMD) são um grupo das doenças clonais de células-tronco caracterizado 
por hematopoese ineficaz, hiperproliferação de medula óssea, citopenias no sangue periférico e risco de 
transformação para leucemia aguda. Decidimos investigar os efeitos de um concentrado de soja em pacientes 
com SMD com base no fato de termos o seguimento de uma paciente japonesa, de 61 anos de idade, que  
foi diagnosticada em 2003 com SMD, citopenia refratária com displasia subtipo multilinhagens  
(hemoglobina = 11 g/dL; contagem de glóbulos brancos = 2.500/uL e plaquetas = 25.000/uL; medula com 
displasia leve e cariótipo normal; hemoglobinúria paroxística excluída), e que começou a usar a soja como 
suplemento alimentar em maio de 2004, apresentando gradual aumento da contagem das células sanguíneas, 
atingindo a normalização cerca de oito meses depois. Entre os componentes da soja, os principais compostos 
com propriedades anticarcinogênese são as isoflavonas (Ge nisteína e daidzeína). Com base nessas linhas de 
evidência, foi proposto oferecer diariamente um concentrado de soja padrão, por um período mínimo de três 
meses e máximo de doze meses, a 14 pacientes ambulatoriais, na tentativa de avaliar, prospectivamente, 
o possível aumento de hemoglobina, neutrófilos e plaquetas. Um grupo controle histórico foi utilizado para 
comparar os resultados. O uso de um concentrado de soja de forma padronizada foi associado ao aumento 
na contagem de neutrófilos e/ou de plaquetas em alguns casos, mas aumentos espontâneos também foram 
observados em controles históricos. Este estudo preliminar não permite estabelecer relação entre o uso de 
soja e o aumento na contagem sanguínea. 
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Introduction
Myelodysplastic syndromes (MDS) are a group of clonal 
diseases of hematopoietic stem cell characterized by ineffective 
production of blood cells, bone marrow hyperproliferation, 
cytopenias in peripheral blood and risk of transformation to 
acute myeloid leukemia (AML) in 30% of patients(3). MDS are 
frequent in older people, with median age at diagnosis at 
Universidade Federal de São Paulo (UNIFESP) of 64 years-old(22).
The first MDS classification was proposed by the French-
American-British (FAB) group in 1982 and included patients 
who had less than 30% of bone marrow blasts and evidences 
of ineffective hematopoesis at diagnosis(3). The World Health 
Organization (WHO) modified the limit of blasts to 20% and 
re-classified the refractory anemia with excess of blasts in 
transformation group (RAEB-t) into acute leukemia (AL)(10). 
According to the WHO, the subtypes of MDS are: refractory 
anemia (RA), 5q- syndrome, refractory anemia with ringed 
sideroblasts (RARS), refractory cytopenia with multilineage 
dysplasia (RCMD), refractory cytopenia with multilineage 
dysplasia and ringed sideroblasts (RCMD and RS), refractory 
anemia with excess of blasts I (RAEB-I), refractory anemia 
with excess of blasts II (RAEB-II) and MDS unclassifiable(10).
In 1997, Greenberg et al. created an International 
Prognostic Scoring System (IPSS) to predict the risk of 
transformation to AL(8). The variables included in this 
system are: karyotype, percentage of blasts in peripheral 
blood (PB) and number of cytopenias in PB. According to 
IPSS the patients are classified as low risk, intermediate 1, 
intermediate 2 and high risk.
The physiopathology of MDS is not well understood 
yet, but apparently it is due to accumulated genomic 
modifications that promote abnormalities in cell maturation 
and differentiation. Clonal expansion induces an ineffective 
hematopoesis that results in anemia, leukopenia or decreased 
platelet counts. There is an enhanced degree of apoptosis 
which contributes to the cytopenias. The evolution of the 
disease is marked by damaged maturation originating 
gradual excess of mieloblasts(11). The therapeutic goal in low 
risk patients is to increase the hemoglobin, neutrophil and 
platelet counts in order to decrease transfusion needs and to 
avoid the incidence of bleeding or infections. In the high risk 
group the objective is to eliminate the abnormal clone(12, 26).
We decided to investigate the effects of a soy concentrate 
in MDS patients based on the fact of having followed-up a 
61 year-old-female Japanese patient who was diagnosed with 
MDS, RCMD subtype, in 2003, (Hb = 11g/dL, white blood 
cell count = 2500/µL and platelets = 25.000/µL, marrow 
aspiration and biopsy with mild dysplasia, compatible 
with MDS, marrow karyotype = 46,XX[20], and paroxistic 
nocturnal hemoglobinuria ruled out), and who started 
using soy as a dietary supplementation in May 2004 and 
presented a gradual increment of her blood counts, achieving 
normalization around eight months afterwards.
Experimental and epidemiological evidences suggest 
that a diet rich on soy products is associated with low 
cancer mortality, mainly neoplasia of breast and prostate(23). 
Among the soy components, the main compounds with 
anti-carcinogenesis properties are the isoflavones (genistein 
and daidzein)(15, 20) Isoflavones have a phenol group in their 
structures and belong to phytoestrogen class(7).
Genistein is associated with the blockade of protein 
tyrosine-kinases activities and inhibition of topoisomerases 
enzyme II that participates in DNA replication, transcription 
and repair(1, 2). Genistein is also related with cell death 
induction in non-small-cell lung cancer (NSCLC) through 
a p53-independent pathway and, thus, may act as an 
anticancer agent(14). High dose of genistein inhibits 
Caco-2BBe human intestinal cells by causing G2/M cell cycle 
arrest(5). Genistein inhibits the growth of human breast and 
prostate cancer cells(17, 18). All of these characteristics result 
in main anti-carcinogenic effect, that blocks the cell growth, 
beyond stimulating apoptosis.
Daidzein has a blockade effect in cell cycle, anti-tumor 
activities on murine neuroblastoma cells and is responsible 
for decreasing the expression of telomerase enzyme in in 
vitro tests with cervix tumor cells(9, 16).
A detailed search was made in electronic database 
Pubmed using descriptive terms and synonymies for soy 
(intervention) and myelodysplastic syndrome (clinical 
situation) and no publication was found relating soy to 
MDS. A second search relating soy (intervention) with the 
following limits: clinical trial, phase I, clinical trial, phase II 
revealed use of isoflavones in postmenopausal women(4).
Based on these lines of evidences, this study was 
designed to be a pilot one to find out if a soy supplement 
could produce an increase in hemoglobin, neutrophils or 
platelet counts in MDS patients who used a standard soy 
concentrate for a minimum of three-month time period 
and maximum of twelve months.
Material and methods
Fourteen patients with the diagnosis of MDS according 
to WHO classification(10) were admitted to the study. Patients 
385
VIANA, T. A. O. F.  et al. Does soy increase blood counts in myelodysplastic syndromes? • J Bras Patol Med Lab •  v. 46 • n. 5 • p. 383-390 • outubro 2010
were selected from the out-patient clinics of Hematology 
Department of UNIFESP/Hospital São Paulo, from March 
2006 till March 2008. Patients agreed to participate after 
informed consent as well as agreed to have blood samples 
collected for analysis whenever established by the protocol 
and to follow all the instructions for the preparation of the 
soy concentrate. The study was approved by the institution 
Ethics Committee (nº. 1207/05).
The inclusion criteria were: MDS patients, at least three 
months after diagnosis (that means they were refractory to 
therapeutic tests with folic acid, 5 mg/day; B12 vitamin, 
5 million of units, and pyridoxine, 900 mg/day for three 
months); not eligible for therapies like: hypomethylating 
agents, chemotherapy or other drugs; and classified as 
low to intermediate grade on prognosis (WHO and IPSS 
classifications).
The exclusion criteria were: Patients, who could not 
properly follow the orientations, refused to collect blood or 
were in use of growth factors like erythropoietin, filgastrine 
or similar ones.
Table 1 shows patients characteristics, like age, sex, 
MDS WHO subtype, IPSS classification, initial hemoglobin, 
neutrophil and platelet counts.
The following aspects were considered as response 
criteria(6):
• erythroid response: for patients with pretreatment 
hemoglobin less than 11 g/dL, an increase in 
hemoglobin level of at least 1.0 g/dL for three 
months in a sustained way; or for patients who 
were transfusion-dependent, a reduction in 50% 
of transfusion needs;
• neutrophil response: for absolute neutrophil count 
less than 1500/mm3 before therapy, at least a 
100% increase, or an absolute count of more than 
500/mm3 for three months;
• platelet response: for patients with pretreatment 
platelet count less 100,000/mm3, a 50% or more 
increase in platelet count; or to become transfusion 
independent for those who were transfusion-
dependent.
The first evaluation was made at 3 months follow-up, 
and then at 6, 9 and 12 months.
In order to have only one kind of soy used for the 
study, the soy used in the study was kindly provided by 
Empresa Brasileira de Pesquisa Agropecuária (EMBRAPA), 
and was of a special seed non-transgenic type (PGA 56.05 
lot Ponta Grossa-PR, Rodovia do Talco km 03, registered 
SEAG number 065), cultivated in a particular region in the 
South of Brazil, obtained from the same crop and harvest.
A standard recipe for the preparation of soy concentrate 
was provided; the patient was oriented to prepare it 
accordingly and to drink one liter of this concentrate daily 
for at least three months. The recipe was: put 500 g of soy 
seed into water and wait for 12 hours; take off the husk, put 
into a mixer, percolate and then seethe; add sugar or fruit 
pulp as wished. The prepared concentrate could be stored in 
a refrigerator and 1 liter of it should be drunk along the day.
A social assistant periodically visited the patient’s home 
to check how the concentrate was being prepared and 
patient’s compliance. Besides that, at each follow-up the 
patient was inquired about his adherence to the protocol 
by the investigators, and about side effects.
Before starting the use of soy concentrate each patient 
was submitted to the following tests: Hb, white blood cells 
count (WBC) with cell differentiation and platelet count, 
which were repeated at each follow-up evaluation.
In each follow-up evaluation patients were questioned 
about symptoms or eventual side effects of the use of soy 
concentrate, were submitted to physical examination and 
blood tests, and transfusion needs were annotated.
A blood sample was collected for quantitation of total 
genistein and daidzein in serum by liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS).
The internal standard (genistein-d3 at 5 µg/mL prepared 
as described by Kiuru and Wähälä[13]) was added to 0.3 mL of 
serum plasma in a 1.5 mL polypropylene tube. This sample 
was treated with 0.25 mL of a mixture of β-glucuronidase/
sulfatase from Helix pomatia to hydrolyze glucuronide and 
sulfate conjugates of genistein and daidzein and 0.75 
mL of 0.2 M pH 4.0 acetate buffer(25). The mixture was 
incubated overnight (15-18 h) at 37ºC. The digestion was 
stopped by the addition of 0.5 mL of 0.2 mol/L ZnSO4/
methanol (20/80) followed by vortexing for more 3 min 
and centrifugation for 10 min at 4000 × g. The supernatant 
was transferred to a polypropylene 96-well deep well plate 
and placed in a Waters 2777 sample manager equipped 
with a cooling stack set at 10ºC.
One milliliter of the supernatants were on-line extracted 
using Onyx monolithic C18 10 x 4.6 mm cartridge 
(Phenomenex, Torrance, CA) connected to a 2-position, 
6-port Phenomenex Synergi fluid processor. Samples were 
loaded and washed with 5% acetonitrile at 4 mL/min 
pumped by a Waters 510 pump (Millford, MA) for 2 min. 
The analytes were eluted for 1.5 min on to a Synergi Fusion 
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4 µ 50 x 2 mm analytical column (Phenomenex) kept at 
50ºC in a Thermasphere TS-130 column oven. The analytical 
column was eluted with a multistep binary gradient pumped 
by a Waters 1525µ pump. The elution mobile phase 
consisted initially of a mixture of 40% (v/v) methanol in 
0.5 mmol/L pH 3.0 ammonium formate at a flow rate of 
0.3 mL/min. The methanol content was increased to 60% 
in 5 minutes using the binary gradient curve 6 and kept at 
60% fir 2.5 minutes.
Detection was performed on a Quattro Premier tandem 
mass spectrometer (Waters, Manchester, UK) equipped 
with an electrospray probe operating at positive mode. The 
mass spectrometer operating conditions were as follows: 
desolvation temperature 400ºC, desolvation gas (nitrogen) 
flow 700 L/h, source temperature 80ºC, cone gas flow 
(nitrogen) 50 L/h, with capillary potential set to 3.5 kV. 
Collision-induced dissociation was performed using argon as 
the collision gas at 4 × 10-3 mbar. For product ion spectra 
and multiple reaction monitoring (MRM) analyses, unit 
resolution was maintained for both parent and product ions. 
Instrument optimization for the analytes were conducted 
by infusing standard solution (1 µg/mL) of the analytes 
by the built-in syringe pump at a flow rate of 10 µL/min 
combined with a makeup-flow of 60% (v/v) methanol in 
0.5 mmol/L pH 3.0 ammonium formate at a flow rate of 
0.3 mL/min. The MRM transitions monitored were m/z: 
255 to 91 and 255 to 199 for daidzein, 271 to 153 and 
271 to 215 for genistein and, 274 to 218 and 274 to 154 
for genistein-d3. The product ions at 91, 153 and 218 were 
quantitative, while the product ions m/z 199, 153 and 154 
were qualitative. System control and data acquisition were 
achieved with the MassLynx 4.0.
Data processing and quantitation were performed by the 
QuanLynx Application Manager. For cortisone, cortisol-d4 
was used as internal standard. Calibration was performed 
using a 6 points curve through linear regression with fit 
weighting to 1/x2 to give higher priority to calibration points 
with a low concentration. The accepted range for ion ratios 
was within 20% of the calibration standards.
As low grade MDS patients present high apoptosis 
index in marrow cells, another point to check was if soy 
use would interfere with this index. Apoptotic rates were 
evaluated in five patients before and six months after soy 
use and in four normal controls. Apoptosis in CD34+ cells 
was determined in bone marrow (BM) mononuclear cells 
by flow cytometry using the annexin V and 7-actinomycin 
D method (Annexin FITC, CD34 PE – clone 8G12, 7AAD – 
Becton-Dickinson, San Jose).
A historical control-group from the same institution was 
searched for each patient studied, matching for sex, age 
and MDS subtype in order to compare differences in blood 
cell counts due to the use of soy concentrate or to detect 
spontaneous increases that could not be credited to soy use. 
The same criteria for diagnosis were adopted to the control 
group. All historical controls data sheets were reviewed and 
special attention was paid to answers to inquires about 
clinical symptoms, transfusion needs, physical examination 
and laboratory results. Table 1 shows the control group 
data. No difference was found between control group and 
patients (Mann Whitney test) at the beginning of the study 
in respect to age (p = 0.81), Hb level (p = 0.42), neutrophil 
count (p = 0.72) and platelet count (p = 0.72). The Fisher 
test was used to compare patients and controls results at 3, 
6, 9 and 12 months in relation to the proportion of response 
to those parameters.
Results
From the 14 MDS patients selected to the intervention 
study group: 8 completed one year of soy use, while 3 
patients completed nine, six and three months, respectively. 
Three patients did not accomplish the minimum period of 
three-months, two of them due to disease complications 
culminating in death (case 2 – death due to sepsis, and case 
14 – death due to bleeding) and one dropped out (case 9).
At the 3rd month evaluation there were 11 patients in the 
study, 4 of which presented neutrophil response (cases 3, 5 
7 and 8), and one of them concomitant platelet response 
(case 7). At the 6th month evaluation, only 10 patients could 
be analyzed, since one died in the fourth month (case 6) due 
to sepsis. Except for case 7 who sustained platelet response 
only, all the others lost their initial responses. At the 9th 
month evaluation, none out of nine patients showed any 
response. Case 10 died due to sepsis after the 6th month. 
At the 12th month evaluation there were 8 patients (case 8 
dropped out at the 10th month of follow-up) and only one 
presented neutrophil response (patient 5 who reacquired 
neutrophil response this time) (Table 2).
So, in the first evaluation, at 3 months, 4 out of 11 
cases presented at least one of the response criteria. These 
patients were classified as refractory anemia with ringed 
sideroblasts (RARS) (cases 3, 5 and 7) and refractory 
cytopenia with multilineage dysplasia (RCMD) (case 8). 
Cases 3, 5 and 8 presented neutrophil response and case 
7 showed neutrophil and platelet responses just in the first 
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1 Characteristics of patients and controls studied: age, WHO subtype, IPSS, Hb level (initial, at 3rd m 
and 12th m), neutrophil count (initial, 3rd m and 12th m) and platelet count (initial, 3rd m and 12th m)
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SS Hemoglobin 
g/dL
Neutrophil count 
X100/uL
Platelet count 
X100/uL
0 m 3 m 6 m 9 m 12 m 0 m 3 m 6 m 9 m 12 m 0 m 3 m 6 m 9 m 12 m
1 72 M RARS LR 8.1* 8,7 6,7 6,9 7,5 7.7 5.7 5.7 7.4 7.9 401 365 382 404 421
2 73 F RAEB-I Int-II 10.7 1.4 - - - 59 - - -
3 79 F RARS LR 9.6* 10.0 9,7 8,2 8,9 1.5 2.3 1.8 1.2 1.5 185 263 185 237 247
4 81 F RA LR 10.6 9,5 9,7 10,3 9,5 7.1 6.1 7.7 8.7 6.2 212 219 219 196 266
5 71 F RARS LR 9.4* 10,3 7,6 7,7 7,2 1.3 2.3 1.6 1.4 2.0 209 177 200 164 192
6 65 F RCMD Int-I 6.3* 6,8 2.3 3.1 - - - 3 3 - - -
7 70 M RARS LR 8.3* 8,6 8,8 8,4 8,2 0.9 2.1 2.8 2.5 0.8 54 85 170 70 48
8 92 M RCMD LR 6.4* 6,6 7,2 9,6 1.5 3.8 1.8 2.0 - 179 232 165 167 -
9 81 M RAEB-I Int-II 10.6 0.7 - - - - 169 - - -
10 63 M RA LR 5.2* 5,2 5,0 0.1 0.3  0.09 - - 6 5 3 - -
11 66 M RCMD -RS Int-I 7.6* 7,5 7,0 6,3 8,0 0.2 0.209 0.43 0.21 0.13 43 41 48 34 44
12 66 F RCMD Int-I 8.0* 8,3 6,8 6,1 8,7 8.0 10.4 6.4 5.4 8.0 103 109 88 75 91
13 66 F RCMD Int-I 9.5 10 8,4 9,0 9,1 0.18 2.6 3.0 2.7 3.3 139 167 160 156 179
14 74 M RARS LR 9.0 3.0 - - - - 158 - - -
Control group 
1 72 M RARS LR 4.5* 8,5 8,8 13,6 11,0 0.52 0.51 0.54 2.4 1.5 68 49 26 143 124
2 73 F RAEB-I Int-I 8.9* 7,6 11 6,9 7,3 0.56 1.07 1.65 1.6 1.12 94 190 182 191 191
3 76 F RARS LR 6.5* 7,2 6,8 5,7 8,9 2.48 1.56 1.5 1.36 1.26 245 215 205 192 138
4 83 F RA LR 11.3 11,8 11,3 10,3 10,2 2.04 1.32 2.04 1.75 2.08 330 270 330 244 255
5 66 F RARS Int-I 6.2* 6,8 5,0 3,7 4,9 2.31 3.64 1.76 1.92 2.31 380 410 250 280 320
6 61 F RCMD Int-I 4.3* 6,2 5,0 7,3 6,8 0.47 0.23 0.48 0.34 0.39 5 4 17 13 18
7 71 M RAEB-I LR 5.8* 5,8 7,6 6,9 8,7 1.27 0.84 0.96 0.96 1.26 30 30 20 18 9
8 85 M RCMD LR 11.8 9,8 11,2 10,9 11,7 5.63 2.45 2.47 1.62 1.8 121 72 110 72 99
9 81 M RAEB-I Int-II 9.7* 8,3 6,7 9,0 7,8 7.03 3.65 4.88 2.42 1.52 20 16* 14* 6* 8*
10 63 M RA LR 9.5* 9,5 9,6 11,5 12,9 1.65 1.25 1.19 1.51 1.45 110 109 137 159 158
11 LR M RCMD RS LR 5.1* 7,0 7,0 6,7 5,2 0.94 1.08 4.05 2.27 0.32 150 135 190 143 32
12 61 F RCMD LR 13.2 13,5 13,8 13,7 13,2 1.08 1.14 2.39 1.22 1.60 65 75 98 91 125
13 62 F RCMD Int-I 5.3* 10,4 11,8 10,2 12,6 0.66 1.30 0.80 1.32 1.62 15* 27 22 29 89
14 78 M RAEB-I LR 6.9* 6,2 5,2 8,2 5,5 2.00 1.46 2.52 3.77 0.50 79 58 80 99 72
M: male; F: female; RA: refractory anemia; RARS: refractory anemia with ringed sideroblasts; RCMD: refractory cytopenia with multilineage dysplasia; RCMD and RS: 
refractory cytopenia with multilineage dysplasia and ringed sideroblasts; RAEB-I: refractory anemia with excess of blasts I; IPSS: International Prognostic Scoring System; 
LR: low risk; Int-I: intermediate I; Int-II: intermediate II. 
* = transfusion-dependent; bold = means when response criteria were met.
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trimester. However, when we applied the same response 
criteria to control group we found that during the same 
period, two control patients also presented spontaneous 
increase in neutrophil counts (36% versus 14.28%, p = 0.35, 
Table 2 Responses of all patients and controls during the study period
Cases Results3rd month 6th month 9th month 12th month
1 No response No response No response No response
2 Death
3 Neutrophils increase No response No response No response
4 No response No response No response No response
5 Neutrophils increase No response No response Neutrophils increase
6 No response Death
7 Neutrophils and  platelets increases platelet increase No response No response
8 Neutrophils increase No response No response Dropped out
9 Dropped out
10 No response No response Death
11 No response No response No response No response
12 No response No response No response No response
13 No response No response No response No response
14 Death
Control group
1 No increase No increase Neutrophils and  platelets increase No increase
2 Neutrophils increase Neutrophils increase No increase No increase
3 No increase No increase No increase No increase
4 No increase Neutrophil increase No increase No increase
5 No increase No increase No increase No increase
6 No increase platelets increase No increase No increase
7 No increase No increase No increase No increase
8 No increase No increase No increase No increase
9 No increase No increase No increase No increase
10 No increase No increase No increase No increase
11 No increase Neutrophils increase No response No increase
12 No increase Neutrophils increase No increase No increase
13 Neutrophils increase Neutrophils increase No increase No increase
14 No increase No increase No increase No increase
Fisher) (Table 2). Applying the same criteria to patients 
and controls at the 6, 9 and 12 month evaluations no 
differences (10% versus 42.8%, p = 0.17; 0% versus 7%, 
p = 1.0; 12.5% versus 0%, p = 0.36, respectively) were 
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detected (Table 2). Thus the increase observed in blood 
counts may have been due to spontaneous variations 
during the follow up, therefore the soy concentrate can 
not be implicated as a contributing factor to blood count 
increases, notwithstanding the sample size that was small. 
During the study period no transfusion dependent 
patient became independent or presented a reduction in 
more then 50% of their transfusion needs.
The plasmatic levels of genistein and dadizen were 
increased as compared to stating levels by LC-MS/MS 
dosage (p = 0.016, t-Test).
The rate of apoptosis on BM CD34+ cells before the soy 
use were 72%, 69.3%, 79.9%, 77% and 40.7% in cases 
3, 4, 5, 7 and 12, respectively (mean rate of 68.6%). The 
mean level of apoptosis on normal controls was 41.7% 
(29.6%-49%) (p = 0.08). Four patients presented reduction 
of apoptotic levels (cases 3, 5, 7 and 12) after six months of 
soy use and one patient presented an increase of CD34+ cells 
annexin positivity (case 4). The apoptotic rate after soy use 
was 36% (case 3), 85% (case 4), 65% (case 5), 62% (case 
7) and 28% (case 12) (p = 0.5). Interestingly, although three 
patients (3, 5 and 7) with apoptosis reduction presented 
increase of neutrophils during soy use this was not significant.
Discussion
This study was designed to find out if a standardized 
soy concentrate used as a dietary supplementation during 
an established period of time, by a group of MDS patients 
not eligible to specific drugs therapies, could offer benefits 
in improvement of hematologic counts, like hemoglobin 
concentration, neutrophil and platelet counts. 
Considering that improvements in cytopenias is a goal in 
the therapeutic intervention of low or intermediate-risk MDS 
patients, the intention in the present study was to find out if the 
soy concentrate would result in any response. The responses 
criteria were established according to previous reports(6).
The use of a soy concentrate in a standardized manner 
induced an increase of neutrophil and/or platelet counts in 
28.5% of patients as compared to their own values at the 
start of the study (Table 1). Most of the responses occurred 
during the first trimester of use (Table 2).
Considering side effects related possibly to soy use, one 
patient complained of nausea and vomiting, another one of 
dark feces and one presented an acute gastroenterocolitis 
crisis, all of them isolated episodes, at the 5th, 6th and 6th 
months of use of soy concentrate, respectively. The control 
group did not present any of these complains. The adverse 
effects detected were sporadic and possibly unrelated to 
soy supplement use.
No vitamin supplementation or therapy was used 
during the period the patient was in the study. In general, 
patients’ adherence to the study was good, except for two 
who dropped out due to intolerance to the taste of soy.
There were four deaths during the study. The number 
of deaths was expected as the natural history of the 
disease. In fact, IPSS median survival estimation for low-risk, 
intermediate 1 and 2 patients are: 5.7 years, 3.5 and 1.2 
years, respectively(8). In the intervention group patients died 
in accordance to these estimations (case 2 in 3.25 years 
versus expected 1,2; case 6 in 3.5 versus 3.5; case 10, 5.1 
versus 5.7) except for case 14 who died 18 days after starting 
the protocol due to a peptic ulcer bleeding, though with 
normal platelet counts, 9 months after diagnosis an with 
an expected survival of 5.7 years.
Apoptosis is an interesting phenomenum in MDS, 
contribuiting to cytopenias, specially in low risk MDS. The 
reduced apoptosis observed in four cases indicates that 
there may be a role to soy in this pathway but more detailed 
studies must be conduct to clear out this aspect.
There were no Japanese patients in the study or control 
group. There are several reports indicating differences in 
clinical features between Asian MDS patients and Western 
ones: the prevalence of MDS in United States is higher when 
compared with Japan(21, 24); the median age in Asian countries 
patients is around 60 versus 68-73 in Western ones(17); the 
RA subtype is more frequent in Asian while the RARS is rarer 
as compared to Western ones(17); considering prognosis, 
Japanese patients were significantly more favorable than that 
of German patients and Japanese patients had a significantly 
lower cumulative risk of acute leukemia evolution than did 
German patients(17). The reasons for these differences are 
unknown. Besides ethnic origins, one of the major differences 
in diet between these populations is that Asian people 
traditionally consume a diet rich in soy products. These data 
suggest that a diet rich on soy products may contribute to 
avoid the occurrence of cancer.
No benefit was found in this preliminary study implicating 
soy as a contributing factor to blood count increases.
Acknowledgments
The authors would like to thank EMBRAPA and Instituto 
Fleury for assistance.
VIANA, T. A. O. F.  et al. Does soy increase blood counts in myelodysplastic syndromes? • J Bras Patol Med Lab •  v. 46 • n. 5 • p. 383-390 • outubro 2010
390
References
1. AKIYAMA, T. et al. Genistein, a specific inhibitor of tyrosine-
specific protein kinases. J Biol Chem, v. 262, n. 12, 
p. 5592-5, 1987.
2. BANDELE, O. J.; OSHEROFF, N. Bioflavonoids as 
poisons of human topoisomerase II alpha and II beta. 
Biochemistry, v. 46, n. 20, p. 6097-108, 2007.
3. BENNETT, J. M. et al. Proposals for the classification of 
the myelodysplastic syndromes. Br J Haematol, v. 51, 
n. 2, p. 189-99, 1982.
4. BLOEDON, L. T. et al. Safety and pharmacokinetics of 
purified soy isoflavones: single-dose administration to 
postmenopausal women. Am J Clin Nutr, v. 76, n. 5, 
p. 1126-37, 2002.
5. CHEN, A. C.; DONOVAN, S. M. Genistein at a concentration 
present in soy infant formula inhibits Caco-2BBe cell 
proliferation by causing G2/M cell cycle arrest. J Nutr, 
v. 134, n. 6, p. 1303-8, 2004.
6. CHESON, B. D. et al. Report of an international working group 
to standardize response criteria for myelodysplastic 
syndromes. Blood, v. 96, n. 12, p. 3671-4, 2000.
7. CHOI, S. Y. et al. Estrogenic activities of isoflavones and 
flavones and their structure-activity relationships. Planta 
Med, v. 74, n. 1, p. 25-32, 2008.
8. GREENBERG, P. et al. International scoring system for 
evaluating prognosis in myelodysplastic syndromes. 
Blood, v. 89, n. 6, p. 2079-88, 1997.
9. GUO, J. M. et al. Effect of daidzein on cell growth, cell 
cycle, and telomerase activity of human cervical cancer 
in vitro. Int J Gynecol Cancer, v. 14, n. 5, p. 882-8, 
2004.
10. HARRIS, N. L. et al. World Health Organization 
classi f icat ion of  neoplast ic diseases of  the 
hematopoietic and lymphoid tissues: report of the 
Clinical Advisory Committee meeting-Airlie House, 
Virginia, November 1997. J Clin Oncol, v. 17, n. 12, 
p. 3835-49, 1999.
11. HIRAI, H. Molecular pathogenesis of MDS. Int J Hematol, 
v. 76, p. 213-21, 2002.
12. HOFMANN, W. K. et al. Therapeutic spectrum in the 
treatment of myelodysplastic syndromes. Expert Opin 
Pharmacother, v. 5, n. 12, p. 2451-8, 2004.
13. KIURU, P. S.; WÄHÄLÄ, K. Expedient microwave 
deuteration of estrone in CF3COOD. Tetrahedron Lett, 
v. 43, p. 3411-2, 2002.
14. LIAN, F. et al. p53-independent apoptosis induced by 
genistein in lung cancer cells. Nutr Cancer, v. 33, 
n. 2, p. 125-31, 1999.
15. LIGGINS, J. et al. Daidzein and genistein content of cereals. 
Eur J Clin Nutr, v. 56, n. 10, p. 961-6, 2002.
16. LO, F. H.; MAK, N. K.; LEUNG, K. N. Studies on the anti-
tumor activities of the soy isoflavone daidzein on murine 
neuroblastoma cells. Biomed Pharmacother, v. 61, 
n. 9, p. 591-5, 2007.
17. MATSUDA, A. et al. Difference in clinical features 
between Japanese and German patients with refractory 
anemia in myelodysplastic syndromes. Blood, v. 106, 
p. 2633-40, 2005.
18. PETERSON, G.; BARNES, S. Genistein and biochanin 
A inhibit the growth of human prostate cancer cells 
but not epidermal growth factor receptor tyrosine 
autophosphorylation. Prostate, v. 22, n. 4, p. 335-459, 
1993.
19. PETERSON, G.; BARNES, S. Genistein inhibition of the 
growth of human breast cancer cells: independence 
from estrogen receptors and the multi-drug resistance 
gene. Biochem Biophys Res Commun, v. 179, n. 1, 
p. 661-7, 1991.
20. REINLI, K.; BLOCK, G. Phytoestrogen content of foods: a 
compendium of literature values. Nutr Cancer, v. 26, 
n. 2, p. 123-48, 1996.
21. ROLLISON, D. E. et al. Epidemiology of myelodysplastic 
syndromes and chronic myeloproliferative disorders 
in the United States, 2001-2004: utilizing data from 
the NAACCR and SEER programs. Blood, v. 112, n. 1, 
p. 45-52, 2008.
22. ROMEO, M. et al. Comparision of cytogenetics with FISH in 
40 myelodysplastic syndrome patients. Leuk Res, v. 26, 
n. 11, p. 993-6, 2002.
23. SARKAR, F. H.; LI, Y. Soy isoflavones and cancer 
prevention. Cancer Invest, v. 21, n. 5, p. 744-57, 2003.
24. SHIMIZU, H. et al. Prevalence of the myelodysplastic 
syndromes in Japan. Int J Hematol, v. 61, n. 1, 
p. 17-22, 1995.
25. THOMAS, B. F. et al. Quantitative analysis of the principle 
soy isoflavones genistein, daidzein and glycitein, and 
their primary conjugated metabolites in human plasma 
and urine using reversed-phase high-performance 
liquid chromatography with ultraviolet detection. 
J Chromatogr B Biomed Sci Appl, v. 760, n. 2, 
p. 191-205, 2001.
26. TRICOT, G. J. Complications and treatment of the 
myelodysplastic syndromes. Leuk Res, v. 16, n. 1, 
p. 117-21, 1992.
Mailing adress
M. L. L. F. Chauffaille
Escola Paulista de Medicina – Universidade 
Federal de São Paulo
Rua Pedro de Toledo, 740 – 3º andar
CEP: 04023-900 – São Paulo-SP
Fax: (11) 5571-8806
e-mail: chauffaille@unifesp.br
VIANA, T. A. O. F.  et al. Does soy increase blood counts in myelodysplastic syndromes? • J Bras Patol Med Lab •  v. 46 • n. 5 • p. 383-390 • outubro 2010
